Cancer Nutshell Therapeutics divulges new TP53 Y220C reactivators May 6, 2025 Nutshell Therapeutics Inc. has synthesized deuterated indolizine compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.Read More
Cancer NTS-071, small-molecule p53 Y220C reactivator with excellent antitumor efficacy in vivo Nov. 15, 2024 NTS-071 is a novel orally bioavailable p53 Y220C reactivator recently discovered and characterized by Nutshell Therapeutics Inc.Read More
